ValuEngine upgraded shares of Nektar Therapeutics (NASDAQ:NKTR) from a hold rating to a buy rating in a report issued on Tuesday morning.

Other research analysts have also issued reports about the company. William Blair reiterated a buy rating on shares of Nektar Therapeutics in a report on Monday, June 4th. HC Wainwright decreased their target price on Nektar Therapeutics to $97.00 and set a buy rating for the company in a report on Monday, June 4th. Canaccord Genuity set a $94.00 target price on Nektar Therapeutics and gave the company a buy rating in a report on Friday, May 11th. Piper Jaffray Companies set a $125.00 target price on Nektar Therapeutics and gave the company a buy rating in a report on Friday, May 11th. Finally, BidaskClub upgraded Nektar Therapeutics from a hold rating to a buy rating in a report on Tuesday, June 19th. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $82.91.

NKTR opened at $66.00 on Tuesday. Nektar Therapeutics has a 52 week low of $18.90 and a 52 week high of $111.36. The firm has a market cap of $11.25 billion, a PE ratio of -120.00 and a beta of 2.08. The company has a quick ratio of 19.55, a current ratio of 19.67 and a debt-to-equity ratio of 0.13.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.22 by $0.11. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.03 billion. Nektar Therapeutics had a return on equity of 174.70% and a net margin of 65.69%. Nektar Therapeutics’s revenue was up 3043.7% compared to the same quarter last year. During the same period last year, the business posted ($0.39) earnings per share. equities research analysts predict that Nektar Therapeutics will post 3.66 earnings per share for the current fiscal year.

In other Nektar Therapeutics news, Director R Scott Greer sold 1,400 shares of the firm’s stock in a transaction on Monday, June 4th. The stock was sold at an average price of $61.99, for a total value of $86,786.00. Following the sale, the director now directly owns 131,733 shares in the company, valued at $8,166,128.67. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dennis L. Winger sold 34,250 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the sale, the director now owns 59,875 shares in the company, valued at $3,628,425. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 263,984 shares of company stock worth $14,141,404. 4.31% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Asset Management One Co. Ltd. acquired a new stake in Nektar Therapeutics in the first quarter valued at $110,000. Daiwa Securities Group Inc. acquired a new stake in Nektar Therapeutics in the first quarter valued at $111,000. We Are One Seven LLC acquired a new stake in Nektar Therapeutics in the first quarter valued at $118,000. Harbor Advisors LLC acquired a new stake in Nektar Therapeutics in the first quarter valued at $213,000. Finally, Canandaigua National Bank & Trust Co. acquired a new stake in Nektar Therapeutics in the first quarter valued at $219,000. Institutional investors own 92.56% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Recommended Story: Moving Average (MA)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.